Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MUMPS
MCID: MMP001
MIFTS: 58

Mumps (MUMPS) malady

Categories: Rare diseases, Infectious diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mumps

About this section

Aliases & Descriptions for Mumps:

Name: Mumps 12 50 52 41 3 42 14 69

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:10264
ICD10 33 B26 B26.9 B26.8
ICD9CM 35 072
MeSH 42 D009107
NCIt 47 C29888
UMLS 69 C0026780
Sources

Summaries for Mumps

About this section
MedlinePlus : 41 mumps is an illness caused by the mumps virus. it starts with fever headache muscle aches tiredness loss of appetite after that, the salivary glands under the ears or jaw become swollen and tender. the swelling can be on one or both sides of the face. symptoms last 7 to 10 days. serious complications are rare. you can catch mumps by being with another person who has it. there is no treatment for mumps, but the measles-mumps-rubella (mmr) vaccine can prevent it. before the routine vaccination program in the united states, mumps was a common illness in infants, children and young adults. now it is a rare disease in the u.s. centers for disease control and prevention

MalaCards based summary : Mumps is related to hepatitis and newcastle disease, and has symptoms including fever, headache and muscle aches. An important gene associated with Mumps is STAT2 (Signal Transducer And Activator Of Transcription 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Vaccines and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, brain and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

CDC : 3 Mumps is a contagious disease caused by a virus. It typically starts with a few days of fever, headache, muscle aches, tiredness, and loss of appetite, followed by swollen salivary glands. You can protect yourself and your family against mumps with vaccination.

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in salivary gland, has material basis in Mumps virus, which is transmitted_by droplet spread of saliva or mucus from the mouth, nose, or throat of an infected person, or transmitted_by contaminated fomites. The infection has symptom fever, has symptom headache, has symptom muscle aches, has symptom tiredness, has symptom loss of appetite, has symptom swollen and tender salivary glands under the ears or jaw on one or both sides of the face.

Wikipedia : 71 Mumps, also known as epidemic parotitis, is a viral disease caused by the mumps virus. Initial signs and... more...

Sources

Related Diseases for Mumps

About this section

Diseases in the Mumps family:

Congenital Mumps

Diseases related to Mumps via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 310)
id Related Disease Score Top Affiliating Genes
1 hepatitis 29.7 HLA-DRB1 IFNG IL10 IL2 TNF
2 newcastle disease 29.1 CD40LG IL2 TNF
3 paralytic poliomyelitis 29.1 IFNG IL2
4 autistic disorder 29.0 HLA-DRB1 IFNG IL10 TNF
5 chorioretinitis 28.9 CD40LG HLA-DRB1 IFNG IL10 TNF
6 congenital mumps 11.9
7 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 11.8
8 measles 11.4
9 rubella 11.4
10 acute disseminated encephalomyelitis 11.2
11 endotheliitis 11.0
12 acute hemorrhagic leukoencephalitis 11.0
13 testicular microlithiasis 10.7
14 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations 10.7
15 salivary gland disease 10.7
16 postinfectious encephalomyelitis 10.7
17 male infertility 10.7
18 immune-mediated encephalomyelitis 10.7
19 orchitis 10.3
20 meningitis 10.3
21 pyridoxal 5'-phosphate-dependent epilepsy 10.2 IL10 TNF
22 aseptic meningitis 10.2
23 trachoma 10.2 CD40LG STAT1 STAT2
24 bilateral parasagittal parieto-occipital polymicrogyria 10.2 HLA-DPB1 HLA-DRB1 TNF
25 tubular renal disease-cardiomyopathy syndrome 10.2 IL10 TNF
26 human immunodeficiency virus infectious disease 10.2 CD40LG HLA-DRB1 TNF
27 skin benign neoplasm 10.2 IL10 STAT1 STAT2
28 parotitis 10.2
29 maturity-onset diabetes of the young 10.1 CD40LG IL10
30 stiff-person syndrome 10.1 CD40LG HLA-DRB1 IFNG
31 steatitis 10.1 IL2 TNF
32 choreatic disease 10.1 CD40LG HLA-DRB1 TNF
33 oral cavity cancer 10.1 CD40LG IFNG TNF
34 acute cholangitis 10.1 CD40LG HLA-DRB1 TNF
35 myofibroma 10.1 HLA-DRB1 IFNG IL10
36 autosomal recessive pericentral pigmentary retinopathy 10.1 IL10RB TNF
37 stocco dos santos syndrome 10.1 IFNG TNF
38 bacterial meningitis 10.1 CD40LG HLA-DRB1 TNF
39 low anorectal malformation 10.1 HLA-DRB1 IL10 TNF
40 peripheral artery disease 10.1 HLA-DRB1 IL10 TNF
41 osteodysplasty precocious of danks mayne and kozlowski 10.1 IFNG IL10 TNF
42 parkinson disease 11 10.1 IFNG IL10 TNF
43 chronic gonorrhea of cervix 10.1 IFNG IL10 STAT1
44 neurotic disorder 10.1 IFNG IL10 TNF
45 reproductive system disease 10.1 CD40LG HLA-DRB1 IL10
46 senile reticular retinal degeneration 10.1 IFNG IL10 TNF
47 pulpitis 10.1 IFNG IL10 TNF
48 ectodermal dysplasia bartalos type 10.1 IFNG IL10 TNF
49 follicular adenoma 10.1 IFNG IL10 TNF
50 distal trisomy 14q 10.1 HLA-DPB1 HLA-DRB1 IFNG TNF

Graphical network of the top 20 diseases related to Mumps:



Diseases related to Mumps
Sources

Symptoms & Phenotypes for Mumps

About this section

Symptoms:

12
  • • fever
  • • headache
  • • muscle aches
  • • tiredness
  • • loss of appetite
  • • swollen

UMLS symptoms related to Mumps:


fever, pruritus

GenomeRNAi Phenotypes related to Mumps according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 IL2 IL2RA STAT1 TNF CD40LG IL10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 IL2 IL2RA STAT1 TNF CD40LG IL10

MGI Mouse Phenotypes related to Mumps:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.15 CD40LG IFNAR2 IFNG IL10 IL10RB IL12RB2
2 immune system MP:0005387 10.1 IL10RB IL12RB2 IL2 IL2RA IRF2 STAT1
3 cardiovascular system MP:0005385 10.06 CD40LG CD46 IFNG IL10 IL12RB2 IL2
4 endocrine/exocrine gland MP:0005379 10.06 IL2RA STAT1 TNF CD40LG IFNG IL10
5 digestive/alimentary MP:0005381 10.03 IFNG IL10 IL10RB IL12RB2 IL2 IL2RA
6 mortality/aging MP:0010768 9.9 CD40LG IFNAR2 IFNG IL10 IL10RB IL2
7 liver/biliary system MP:0005370 9.8 IFNG IL10 IL10RB IL12RB2 IL2 STAT1
8 neoplasm MP:0002006 9.5 IFNAR2 IFNG IL10 IL12RB2 IL2 STAT1
9 vision/eye MP:0005391 9.17 IFNG IL10 IL2 IL2RA STAT1 TNF
Sources

Drugs & Therapeutics for Mumps

About this section

Drugs for Mumps (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
2 Immunoglobulins Phase 4,Phase 2,Phase 1
3 Antibodies Phase 4,Phase 2,Phase 1
4 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
5 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
6 Liver Extracts Phase 4
7
Tetracycline Approved, Vet_approved Phase 3,Phase 2 60-54-8 5353990
8
Aluminum hydroxide Approved Phase 3,Phase 2 21645-51-2
9
Lactitol Phase 3,Phase 2 585-86-4 3871
10 PENTA Phase 3,Phase 2
11 Anti-Bacterial Agents Phase 3,Phase 2
12 Anti-Infective Agents Phase 3,Phase 2
13
Daclizumab Approved, Investigational Phase 2 152923-56-3
14
Altretamine Approved Phase 2 645-05-6 2123
15
Mycophenolic acid Approved Phase 2 24280-93-1 446541
16
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
17
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
18
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
19
Obinutuzumab Approved Phase 2,Phase 1 949142-50-1
20
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
21 Interleukin-2 Phase 2
22 Peripheral Nervous System Agents Phase 2
23 Immunoglobulin G Phase 2
24 Antibodies, Monoclonal Phase 2
25 Immunosuppressive Agents Phase 2
26 Fibrinolytic Agents Phase 2
27 Anticoagulants Phase 2
28 Prednisolone acetate Phase 2
29 glucocorticoids Phase 2
30 Gastrointestinal Agents Phase 2
31 Neuroprotective Agents Phase 2
32 Hormone Antagonists Phase 2
33 Hormones Phase 2
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
35 Prednisolone hemisuccinate Phase 2
36 Prednisolone phosphate Phase 2
37 Protective Agents Phase 2
38 Antiemetics Phase 2
39 Anti-Inflammatory Agents Phase 2
40 Antibiotics, Antitubercular Phase 2
41 Methylprednisolone acetate Phase 2
42 Methylprednisolone Hemisuccinate Phase 2
43 Autonomic Agents Phase 2
44 Antineoplastic Agents, Hormonal Phase 2
45 gamma-Globulins Phase 1
46 Immunoglobulins, Intravenous Phase 1
47 Rho(D) Immune Globulin Phase 1
48
Acetylcholine Approved 51-84-3 187
49
Methotrexate Approved 1959-05-2, 59-05-2 126941
50
Azathioprine Approved 446-86-6 2265

Interventional clinical trials:

(show top 50) (show all 131)
id Name Status NCT ID Phase
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
3 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
4 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
5 Measles, Mumps, and Rubella (MMR) Immunity in College Students Completed NCT00962819 Phase 4
6 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
7 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
8 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
9 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
10 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
11 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
12 MMR and Varicella Vaccine in Premature Infants Completed NCT00156559 Phase 4
13 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
14 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
15 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
16 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Recruiting NCT02880865 Phase 4
17 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
18 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Recruiting NCT01770119 Phase 4
19 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Active, not recruiting NCT02325310 Phase 4
20 Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines Terminated NCT00138255 Phase 4
21 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
22 A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) Completed NCT00092391 Phase 3
23 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3
24 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
25 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
26 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
27 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3
28 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Completed NCT00092430 Phase 3
29 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
30 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
31 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
32 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
33 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
34 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children Completed NCT00192491 Phase 3
35 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed NCT00197015 Phase 3
36 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed NCT00226499 Phase 3
37 ProQuadâ„¢ Versus M-M-R IIâ„¢ and VARIVAXâ„¢ in Healthy Children (V221-009)(COMPLETED) Completed NCT00975507 Phase 3
38 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed NCT00969436 Phase 3
39 Immunogenicity and Safety Study of PriorixTetraâ„¢ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed NCT01506193 Phase 3
40 ProQuad® rHA Safety Completed NCT00560755 Phase 3
41 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly Completed NCT00432042 Phase 3
42 Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine Completed NCT00406211 Phase 3
43 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
44 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed NCT00985153 Phase 3
45 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed NCT00985166 Phase 3
46 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed NCT00422292 Phase 3
47 ProQuad® Intramuscular vs Subcutaneous Completed NCT00402831 Phase 3
48 Immunogenicity and Safety of Concomitant Administration of MMRâ„¢ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route Completed NCT00432523 Phase 3
49 Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA Completed NCT00566527 Phase 3
50 Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years Completed NCT00871117 Phase 3

Search NIH Clinical Center for Mumps

Cochrane evidence based reviews: mumps

Sources

Genetic Tests for Mumps

About this section
Sources

Anatomical Context for Mumps

About this section

MalaCards organs/tissues related to Mumps:

39
Salivary Gland, Brain, Testes, B Cells, T Cells, Endothelial, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Mumps:

18
Salivary Gl
Sources

Publications for Mumps

About this section

Articles related to Mumps:

(show top 50) (show all 793)
id Title Authors Year
1
Complete Genome Sequence of Mumps Virus Isolated from Karnataka State, India. ( 28082488 )
2017
2
Mumps Epidemiology and Mumps Virus Genotypes Circulating in Mainland China during 2013-2015. ( 28085897 )
2017
3
Heat shock protein 90 ensures efficient mumps virus replication by assisting with viral polymerase complex formation. ( 28053100 )
2017
4
Mumps makes a comeback: What nurses need to know. ( 28027128 )
2017
5
Pancreatic pseudocyst after measles, mumps, and rubella vaccination. ( 28082255 )
2017
6
Mumps transmission in social networks: a cohort study. ( 28068914 )
2017
7
How will the MMR universal mass vaccination change the epidemiologic pattern of mumps? A 2012 Italian serosurvey. ( 27156389 )
2016
8
Mumps Outbreak at a University and Recommendation for a Third Dose of Measles-Mumps-Rubella Vaccine - Illinois, 2015-2016. ( 27467572 )
2016
9
Waning immunity against mumps in vaccinated young adults, France 2013. ( 26987576 )
2016
10
Mumps virus induces innate immune responses in mouse ovarian granulosa cells through the activation of Toll-like receptor 2 and retinoic acid-inducible gene I. ( 27477784 )
2016
11
Seroprevalences of Specific IgG Antibodies to Measles, Mumps, and Rubella in Korean Infants. ( 27822935 )
2016
12
Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-analysis. ( 27163657 )
2016
13
Mumps Presenting as a Parotid Abscess. ( 27159869 )
2016
14
Mumps Virus Induces Protein-Kinase-R-Dependent Stress Granules, Partly Suppressing Type III Interferon Production. ( 27560627 )
2016
15
Recombinant mumps viruses expressing the batMuV fusion glycoprotein are highly fusion-active and neurovirulent. ( 27590163 )
2016
16
Cross-reactive and cross-neutralizing activity of human mumps antibodies against a novel mumps virus from bats. ( 27811320 )
2016
17
Mumps Outbreak Among a Highly Vaccinated University Community-New York City, January-April 2014. ( 27927872 )
2016
18
Mumps Virus Nucleoprotein Enhances Phosphorylation of the Phosphoprotein by Polo-Like Kinase 1. ( 26608325 )
2016
19
Mumps Virus: Modification of the Identify-Isolate-Inform Tool for Frontline Healthcare Providers. ( 27625709 )
2016
20
Vaccine-Preventable Diseases In Pediatric Patients: A Review Of Measles, Mumps, Rubella, And Varicella. ( 27893360 )
2016
21
Challenges in interpreting diagnostic test results in a mumps outbreak in a highly vaccinated population. ( 28003216 )
2016
22
Measles, mumps, rubella, and varicella seroprevalence in refugees in Germany in 2015. ( 27449329 )
2016
23
Molecular epidemiological study of mumps epidemics of 2015 in Okinawa, Japan. ( 28003601 )
2016
24
Chronological changes of mumps virus genotypes in Japan between 1999-2013. ( 27206988 )
2016
25
Measles-Mumps-Rubella vaccine for children with egg allergy: Is admission for inpatient vaccination necessary? ( 27770112 )
2016
26
Protective effect of vaccination against mumps complications, Czech Republic, 2007-2012. ( 27036176 )
2016
27
Unilateral Optic Neuritis: A Rare Complication after Measles-Mumps-Rubella Vaccination in a 30-Year-Old Woman. ( 27195163 )
2016
28
Three cases of mumps virus and enterovirus coinfection in children with enteroviral meningitis. ( 27930588 )
2016
29
Anti-rubella, Mumps and Measles IgG Antibodies in Medical Students of Tehran University. ( 27424140 )
2016
30
Aseptic meningitis after measles-mumps-rubella (MMR) vaccination. ( 27181175 )
2016
31
Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand. ( 27138005 )
2016
32
Releasing the genomic RNA sequestered in the mumps virus nucleocapsid. ( 27581981 )
2016
33
High levels of susceptibility to measles, mumps and rubella (MMR) in HIV-infected individuals in Ireland. ( 27118245 )
2016
34
A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process. ( 27149048 )
2016
35
Purification of mumps virus particles of high viability. ( 26992653 )
2016
36
Cross-neutralization between three mumps viruses & mapping of haemagglutinin-neuraminidase (HN) epitopes. ( 26997012 )
2016
37
Mumps, measles and rubella vaccination in children with PFAPA syndrome. ( 27997341 )
2016
38
Mumps virus F gene and HN gene sequencing as a molecular tool to study mumps virus transmission. ( 27590714 )
2016
39
Systematic review and meta-analysis of the association between mumps during childhood and risk of type 1 diabetes mellitus. ( 27658134 )
2016
40
Recombinant mumps virus as a cancer therapeutic agent. ( 27556105 )
2016
41
Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review. ( 27488917 )
2016
42
Iodide Mumps Complicating Coronary and Carotid Angiography. ( 27649884 )
2016
43
Intralesional mumps, measles and rubella vaccine in the treatment of cutaneous warts. ( 27088951 )
2016
44
Mumps in the Czech Republic in 2013: Clinical Characteristics, Mumps Virus Genotyping, and Epidemiological Links. ( 27070966 )
2016
45
Estimating true hospital morbidity of complications associated with mumps outbreak, England, 2004/05. ( 27562958 )
2016
46
Evidence of Mumps Infection Among Children in the Democratic Republic of Congo. ( 28002360 )
2016
47
Still a pain in the neck after all this time: a case report of mumps in a previously immunized adult diagnosed in the ED. ( 27534433 )
2016
48
Mumps virus pathogenesis: Insights and knowledge gaps. ( 27455055 )
2016
49
Anesthesia mumps after thyroidectomy. ( 28000179 )
2016
50
Complete genome sequence of mumps viruses isolated from patients with parotitis, pancreatitis and encephalitis in India. ( 26876221 )
2016
Sources

Variations for Mumps

About this section
Sources

Expression for Mumps

About this section
Search GEO for disease gene expression data for Mumps.
Sources

Pathways for Mumps

About this section

Pathways related to Mumps according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Super pathways Score Top Affiliating Genes
1
Innate Immune System 62
Show member pathways
 13.96 CD40LG CD46 HLA-DPB1 HLA-DRB1 IFNAR2 IFNG
2
ERK Signaling 60
Show member pathways
 13.86 CD40LG IL10 IL10RB IL12RB2 IL2 IL2RA
3
PEDF Induced Signaling 60
Show member pathways
 13.68 CD40LG IFNAR2 IFNG IL10 IL10RB IL12RB2
4
TGF-Beta Pathway 60
Show member pathways
 13.58 IFNAR2 IFNG IL10 IL10RB IL12RB2 IL2
5
Akt Signaling 60
Show member pathways
 13.45 CD40LG IL10 IL10RB IL12RB2 IL2 IL2RA
6
PAK Pathway 60
Show member pathways
 13.32 CD40LG IL10 IL10RB IL12RB2 IL2 IL2RA
7
IL-2 Pathway 60
Show member pathways
 13.23 HLA-DRB1 IFNG IL2 IL2RA STAT1 STAT2
8
Cytokine Signaling in Immune system 62
Show member pathways
 13.11 CD40LG HLA-DPB1 HLA-DRB1 IFNAR2 IFNG IL10
9
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 12.98 IFNAR2 IFNG IL10 IL2 STAT1 STAT2
10
Allograft rejection 1 37
Show member pathways
 12.9 CD40LG HLA-DPB1 HLA-DRB1 IFNG IL10 IL2
11
Influenza A 37
Show member pathways
 12.82 CD46 HLA-DPB1 HLA-DRB1 IFNAR2 IFNG IL2
12
Immune response IL-23 signaling pathway 21
Show member pathways
 12.67 IFNG IL10 IL10RB IL2 STAT1 TNF
13
Interferon gamma signaling 62
Show member pathways
 12.63 HLA-DPB1 HLA-DRB1 IFNAR2 IFNG IRF2 STAT1
14
Th17 cell differentiation 37
Show member pathways
 12.6 HLA-DPB1 HLA-DRB1 IFNG IL10 IL10RB IL12RB2
15
Immune response Role of DAP12 receptors in NK cells 21
Show member pathways
 12.52 IFNAR2 IFNG IL2 TNF
16
NF-kappaB Signaling 4
12.52 CD40LG CD46 IFNG IL10 IL2 IL2RA
17
T cell receptor signaling pathway 37
Show member pathways
 12.49 CD40LG IFNG IL10 IL2 TNF
18
HTLV-I infection 37
12.49 HLA-DPB1 HLA-DRB1 IL2 IL2RA TNF
19
ICos-ICosL Pathway in T-Helper Cell 60
Show member pathways
 12.41 CD40LG HLA-DRB1 IL2 IL2RA
20
Epstein-Barr virus infection 37
12.38 HLA-DPB1 HLA-DRB1 IFNG IL10 IL10RB
21
Type I Interferon Signaling Pathways 61
Show member pathways
 12.34 IFNAR2 IFNG STAT1 STAT2
22
Tuberculosis 37
12.33 HLA-DPB1 HLA-DRB1 IFNG IL10 IL10RB STAT1
23
Toxoplasmosis 37
Show member pathways
 12.33 CD40LG HLA-DPB1 HLA-DRB1 IFNG IL10 IL10RB
24
Immune response NFAT in immune response 21
Show member pathways
 12.25 CD40LG HLA-DPB1 HLA-DRB1 IFNAR2 IFNG IL10
25
Immune response IFN alpha/beta signaling pathway 21
Show member pathways
 12.22 IFNAR2 IFNG IL10 IL2 IRF2 STAT1
26
Osteoclast differentiation 37
12.15 IFNAR2 IFNG STAT1 STAT2 TNF
27
Jak-STAT signaling pathway (KEGG) 37
Show member pathways
 12.15 IFNAR2 IFNG IL10 IL10RB IL12RB2 IL2
28
IL-2 Signaling Pathway 1
Show member pathways
 12.13 IFNG IL2 IL2RA STAT1
29
Hepatitis C 37
12.12 IFNAR2 STAT1 STAT2 TNF
30
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 61
12.1 IFNG IL10 IL2 IL2RA TNF
31
IL12-mediated signaling events 1
Show member pathways
 12.1 HLA-DRB1 IFNG IL12RB2 IL2 IL2RA STAT1
32
IL27-mediated signaling events 1
Show member pathways
 12.05 IFNG IL10 IL12RB2 IL2 STAT1 STAT2
33
MAPK Pathway 68
Show member pathways
 12.01 IL2 IL2RA STAT1
34
Spinal Cord Injury 1
12 IFNG IL2 TNF
35
Interleukin-4 and 13 signaling 62
11.97 IL10 STAT1 TNF
36
Hematopoietic cell lineage 37
11.97 HLA-DPB1 HLA-DRB1 IL2RA TNF
37
Jak-Stat Signaling Pathway (sino) 63
11.96 IL10RB IL12RB2 IL2RA STAT1 STAT2
38
Rheumatoid arthritis 37
11.93 HLA-DPB1 HLA-DRB1 IFNG TNF
39
Innate Lymphoid Cell Differentiation Pathways 61
11.9 IFNG IL10 IL12RB2 IL2 IL2RA TNF
40
Amoebiasis 37
11.89 IFNG IL10 TNF
41
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.88 CD40LG IFNG IL2 IL2RA TNF
42
Dendritic Cells Developmental Lineage Pathway 61
11.88 IFNG IL10 IL2 IRF2 TNF
43
Glucocorticoid receptor regulatory network 1
11.82 IFNG IL2 STAT1
44
IgA-Producing B Cells in the Intestine 61
11.82 CD40LG IL10 IL2RA TNF
45
CXCR4-mediated signaling events 1
11.79 HLA-DRB1 STAT1 STAT2
46
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.77 CD40LG IFNG IL2 TNF
47
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.77 IFNAR2 IFNG IL2 IL2RA TNF
48
Regulation of Telomerase 1
11.72 IFNAR2 IFNG IL2
49
TGF-beta Receptor Signaling (WikiPathways) 1
11.66 IFNG STAT1 TNF
50
Staphylococcus aureus infection 37
11.65 HLA-DPB1 HLA-DRB1 IL10
Sources

GO Terms for Mumps

About this section

Cellular components related to Mumps according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.43 CD40LG CD46 HLA-DPB1 HLA-DRB1 IL2RA TNF
2 MHC class II protein complex GO:0042613 9.16 HLA-DPB1 HLA-DRB1
3 external side of plasma membrane GO:0009897 9.1 CD40LG HLA-DRB1 IFNG IL12RB2 IL2RA TNF

Biological processes related to Mumps according to GeneCards Suite gene sharing:

(show all 38)
id Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.99 CD46 HLA-DPB1 HLA-DRB1 IL2 IL2RA
2 inflammatory response GO:0006954 9.95 CD40LG IL10 IL10RB IL2RA TNF
3 cell surface receptor signaling pathway GO:0007166 9.94 IFNAR2 IFNG IL12RB2 IL2RA
4 cellular response to lipopolysaccharide GO:0071222 9.85 IFNG IL10 TNF
5 response to virus GO:0009615 9.84 IFNAR2 IFNG TNF
6 negative regulation of inflammatory response GO:0050728 9.8 IL10 IL2 IL2RA
7 T cell costimulation GO:0031295 9.79 CD40LG HLA-DPB1 HLA-DRB1
8 antigen processing and presentation GO:0019882 9.74 HLA-DPB1 HLA-DRB1 IFNG
9 defense response to virus GO:0051607 9.72 IFNAR2 IFNG IL10RB STAT1 STAT2
10 negative regulation of T cell proliferation GO:0042130 9.71 HLA-DRB1 IL10 IL2RA
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 IL10 TNF
12 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.67 IFNG TNF
13 type I interferon signaling pathway GO:0060337 9.67 IFNAR2 IRF2 STAT1 STAT2
14 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.66 HLA-DPB1 HLA-DRB1
15 inflammatory response to antigenic stimulus GO:0002437 9.66 HLA-DRB1 IL2RA
16 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.65 IFNG STAT1
17 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 IL10 TNF
18 JAK-STAT cascade GO:0007259 9.65 IFNAR2 STAT1 STAT2
19 positive regulation of regulatory T cell differentiation GO:0045591 9.64 CD46 IL2
20 positive regulation of chemokine biosynthetic process GO:0045080 9.63 IFNG TNF
21 positive regulation of isotype switching to IgG isotypes GO:0048304 9.63 IFNG IL2
22 regulation of type I interferon-mediated signaling pathway GO:0060338 9.63 IFNAR2 STAT1 STAT2
23 response to interferon-beta GO:0035456 9.61 IFNAR2 STAT1
24 endothelial cell apoptotic process GO:0072577 9.61 IL10 TNF
25 immune response GO:0006955 9.61 CD40LG HLA-DPB1 HLA-DRB1 IFNG IL10 IL10RB
26 positive regulation of MHC class II biosynthetic process GO:0045348 9.6 IFNG IL10
27 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 IL10 TNF
28 negative regulation of lymphocyte proliferation GO:0050672 9.58 IL2 IL2RA
29 negative regulation of growth of symbiont in host GO:0044130 9.58 IFNG IL10 TNF
30 regulation of immunoglobulin secretion GO:0051023 9.56 CD40LG TNF
31 positive regulation of interferon-gamma production GO:0032729 9.56 HLA-DPB1 IL12RB2 IL2 TNF
32 interferon-gamma-mediated signaling pathway GO:0060333 9.55 HLA-DPB1 HLA-DRB1 IFNG IRF2 STAT1
33 receptor biosynthetic process GO:0032800 9.52 IL10 TNF
34 regulation of T cell homeostatic proliferation GO:0046013 9.51 IL2 IL2RA
35 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
36 positive regulation of vitamin D biosynthetic process GO:0060557 9.43 IFNG TNF
37 positive regulation of T cell proliferation GO:0042102 9.1 CD40LG CD46 HLA-DPB1 IFNG IL2 IL2RA
38 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.12 IFNG IL10 IL2 IRF2 STAT1 TNF

Molecular functions related to Mumps according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.13 CD40LG STAT1 TNF
2 cytokine activity GO:0005125 9.02 CD40LG IFNG IL10 IL2 TNF
Sources

Sources for Mumps

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....